Zydus Acquires Assertio in $225 Million All-Cash Transaction

Zydus Lifesciences to Acquire Assertio Holdings in $166.4 Million Deal

Zydus Lifesciences has signed an agreement to acquire US-based Assertio Holdings in an all-cash deal worth approximately $166.4 million (Rs.1600 crore), marking a strategic push into specialty and oncology markets in the United States. The acquisition is expected to strengthen Zydus's presence in the high-value specialty segment and provide a platform to scale its presence in the US market.

Under the terms of the deal, Zydus will acquire all outstanding shares of Assertio at $23.50 per share through a tender offer followed by a merger. The transaction is expected to close in FY27, subject to customary regulatory approvals and shareholder acceptance. Upon successful completion of the transaction, Assertio will be delisted from Nasdaq.

Assertio has revenue of $68.23 million in 2025 and is a specialty pharmaceutical company focused on oncology supportive care. The company's commercial portfolio is anchored by Rolvedon (eflapegrastim-xnst), a long-acting G-CSF (Granulocyte Colony-Stimulating Factor) used to reduce infection risk in cancer patients undergoing chemotherapy.

Read also: Treasury Yields Experience Largest Increase in Two Weeks Following Release of Labor Market Data

The acquisition offers Zydus immediate access to a ready-made US specialty commercial platform, including established oncology relationships and distribution capabilities. The company plans to leverage this infrastructure to scale its presence in the high-value specialty segment.

The deal structure involves a tender offer where Zydus will seek to acquire a majority stake from shareholders, followed by a second-step merger to buy out remaining shares at the same price. This transaction represents a strategic step in strengthening Zydus's specialty and oncology footprint in the US, said Managing Director Sharvil Patel.

The acquisition is significant for Zydus as it accelerates its shift from generics to specialty therapies, particularly in the US where margins are higher but entry barriers are steeper. Instead of building commercial capabilities from scratch, the company gains instant access to a specialized oncology sales network and an approved biologic asset.

Read also: US-Iran Tensions Spark Uptick in Oil Prices Amid Global Market Decline

Assertio's has over 170 community oncology accounts and buy-and-bill infrastructure offers a ready-made base to build a broader oncology platform. The acquisition also strengthens Zydus's position in oncology supportive care—a niche but growing segment—while providing a platform to cross-sell future products and expand its specialty pipeline in developed markets.

More broadly, the move reflects a growing trend among Indian drugmakers to pivot toward complex generics, specialty drugs, and biologics to offset pricing pressure in traditional generics. With the Assertio acquisition, Zydus is effectively buying not just a product portfolio but a commercial entry point into the US specialty market, positioning itself for higher-value growth beyond its core generics business.